Q&A: Transitioning Myeloma Care to the Community Level
Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according to Diane Moran, RN, MA, EdM.
NCCN Adds Taletrectinib to ROS1+ NSCLC Recommendations
The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer harboring ROS1 mutations.
Frontline Ibrutinib/Venetoclax Yields Response in Older Patients With MCL
The frontline combination of ibrutinib with venetoclax was associated with complete response and durable remission for older patients with MCL.
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC
Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.
WRN Inhibitors May Address Immunotherapy Resistance in MSI+ Tumors
Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.
Dato-DXd Greenlit by FDA for Previously Treated EGFR-Mutated NSCLC
Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy.
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.
Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer
The novel MEK inhibitor atebimetinib plus chemotherapy showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.
Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment
Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.
Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in Myelofibrosis
Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.
Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer
Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma
The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma.
No One Should Face Cancer Alone: The Power of Community in Cancer Care
Ask patients, "Who's in your corner?"
Oncology Nurses Aid BC Survivorship and Lymphedema Prevention
Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.
Opinion: Topical BRAF Inhibitor Could Reduce Rash in Anti-EGFR Therapy
Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.
The Evolving Role of the Oncology Nurse in Clinical Trials
Oncology nurses are paramount to the treatment success of patients, especially through their work on clinical trials.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.
Case Study: Bridging the Gap for Patients With Metastatic CRC
Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.
FDA Approves Perioperative Pembrolizumab in Head and Neck SCC
The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.
Zanubrutinib Tablets Greenlit by FDA for All Approved Indications
An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.
FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC
UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Nivolumab/Ipilimumab to Be New MSI-H/dMMR mCRC Standard of Care
Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.
Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer
The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.
AI Tool May Predict Response, Resistance in Advanced RCC
A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.
Creating Safe Spaces for LGBTQIA+ Patients With Cancer
Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ community.
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
